To rescue, repair, and restore health in patients suffering from debilitating and sometimes deadly diseases
We power science to drive breakthroughs…
We strive relentlessly to achieve our goals…
We support each other and humankind to reach our highest potential as a force for good.
EOM Pharmaceuticals was founded with a specific vision to pursue innovative approaches to solving the problems of urgent and unmet medical needs. The EOM team is led by an accomplished team with a deep legacy in multiple therapeutic areas and drug development.
EOM’s pipeline is built on novel compounds with the potential to transform therapeutic paradigms and potentially improve quality of life in patients suffering from debilitating and sometimes deadly diseases. EOM pharmaceuticals has two pipeline assets in their portfolio, EOM613 and EOM147
CEO and Director
Dr. Irach Taraporewala is the CEO and Director of EOM Pharmaceuticals, and is a highly seasoned pharmaceutical company executive with specific experience in leadership of start-up pharmaceutical companies and over 25 years of experience in drug development and regulatory strategy.
Dr. Taraporewala has multiple accomplishments in drug discovery, development and delivery, pharmaceutical formulations, medical devices, radiopharmaceuticals, DNA diagnostics and in pharmaceutical regulatory affairs. His R&D contributions span several therapeutic areas including ophthalmology, cancer, inflammation, immunology, endocrine, CNS, infectious disease, malaria and cachexia.
During his tenure at Advanced Viral Research Corp., he led the chemistry and manufacturing teams in the development of the current processes for the formulation, manufacture and testing of EOM613, enabling the cachexia clinical trials of that drug product.
Prior to EOM Pharmaceuticals, Dr. Taraporewala was the founder, CEO, President, and Board member of OHR Pharmaceutical. During his 5-year tenure, Dr. Taraporewala acquired the antiangiogenic steroid compound squalamine, formulated it as an eye drop and led the drug development of the company’s oncology and ophthalmic products from the lab bench into successful Phase II clinical trials in cancer cachexia, macular degeneration, retinal vein occlusions and macular edema. He secured several rounds of funding leading to remarkable company growth and OHR’s listing on NASDAQ. He accomplished the successful acquisition by OHR of SKS Ocular, a company focused on ophthalmic sustained release microparticle-based drug delivery, and founded DepYmed, Inc., a joint venture oncology company, in partnership with Cold Spring Harbor Laboratory. Dr. Taraporewala took the company from a penny stock OTC with a market capitalization of $5 million to a NASDAQ-listed corporation with a market cap of over $200 millions.
Dr. Taraporewala earned his Bachelors’ and Masters’ degrees in Chemistry and Microbiology from the University of Bombay, India, and a Ph.D. in Medicinal Chemistry from the Philadelphia College of Pharmacy. He conducted postdoctoral academic research at the University of Texas at Austin, the University of Minnesota, and the Southwest Foundation for Biomedical Research in San Antonio, prior to beginning his industrial pharmaceutical career at the multinational CIBA-GEIGY pharmaceutical corporation.
Founder, Chairman & Chief Operating Officer
Eli Goldberger is Founder, Chairman and Chief Operating Officer of EOM Pharmaceuticals, and a successful entrepreneur, focusing on advancing innovations in pharmaceuticals, women’s health and energy.
He is also the founder of Preprogen LLC., a company dedicated to improving global healthcare for women. and he currently serves on the Board of Directors of Universal Energy Corp. Formerly, Mr. Goldberger was Founder & CEO of Payday Solutions, a regional payroll and human capital management company.
Co-Founder, Chief Scientific Officer & Medical Director
Dr. Shalom Z. Hirschman is the Co-founder, Chief Scientific Officer and Medical Director of EOM Pharmaceuticals and has had a long and illustrious career as an academic physician, research scientist, educator, biotechnology entrepreneur and consultant. A graduate of the Albert Einstein College of Medicine, Dr. Hirschman served as intern and resident in medicine at The Massachusetts General Hospital of the Harvard Medical School followed by years of conducting research in molecular biology at the National Institutes of Health in Bethesda, MD. He joined the world-renowned founding faculty of The Mount Sinai School of Medicine where he was appointed as Director of the Division of Infectious Diseases and Professor of Medicine.
For several years Dr. Hirschman also served as vice-chairman of the Department of Medicine. After three decades, he retired from Mount Sinai and joined Advanced Viral Research Corp. as its chief executive officer, president, and chief scientific officer. There he successfully created a new type of peptide-based drug, built an FDA approved manufacturing facility and brought this drug into clinical trials under INDs with the US FDA. He retired from this position and since has served as consultant to educational institutions, biotechnology companies and biotechnology investment funds. Dr. Hirschman was the founder of Xtramedics, the forerunner company of QuantRx, and currently serves as a member of the board. Dr. Hirschman is one of the three founders of Touro College and the Touro University System. He initiated and negotiated the purchase of New York Medical College by Touro College.
Dr. Hirschman has been a member of many distinguished professional bodies including the American Society for Microbiology, the Biophysical Society, the American Association for the Advancement of Science, the American Society for the Study of Liver Diseases, the American Federation for Clinical Research, The Harvey Society and the American Medical Association. He served as Vice Chairman of the Microbiology Section, NY Academy of Sciences and then as Chairman.
Dr. Hirschman was elected to membership and fellowship in the American College of Physicians, the Infectious Diseases Society of America, the Royal Society of Tropical Medicine and Hygiene, the American Society for Clinical Investigation, the Association of American Physicians, the Society for Experimental Biology and Medicine, the American College of Clinical Pharmacology and the Molecular Medicine Society.
Chief Financial Officer & Treasurer
Wayne I. Danson, CPA, is the Chief Financial Officer and Treasurer of EOM Pharmaceuticals who has over 35 years of experience in international and corporate taxation, financial advisory services including investment banking and mergers and acquisitions (M&A), business strategy, corporate finance, including tax structuring and planning, turnaround consulting and entrepreneurship. As a former Partner in large multinational accounting firms and a former Chief Executive Officer and Board member of one of the largest reverse logistics organizations in the country, his technical and corporate financial abilities have proven to be a successful combination.
Prior to EOM, Mr. Danson co-founded JDAP Capital Advisors, LLC a private investment management firm with a strategic focus on the U.S. equity options market using a relative value/market neutral investment strategy and founded Encompass Group Affiliates, Inc., a publicly traded logistics organization that as President, CEO and Chairman of the Board, he grew the business to over $100 million in sales.
Since 1999, Mr. Danson has been President and Chief Executive Officer of Danson Partners, LLC, a financial advisory and business consulting firm, specializing in corporate finance, mergers and acquisitions, business strategy, management consulting, interim CEO/CFO and turnaround consulting, as well as sophisticated tax services. Prior to forming Danson Partners, LLC, he held partnership and leadership positions with PricewaterhouseCoopers and Ernst & Young, where he was a Managing Tax Partner.
Mr. Danson is currently the lead Independent Board Member and Audit Committee Chair of Optigenex, Inc. a publicly traded company in the nutraceutical/health supplement industry. He is also a member on the Strategic Advisory Boards of Red Lion, LLC, a cybersecurity service and software platform company and Safe Luna, an Israeli medical device start-up, as well as Chairman of the Board of The chILD Foundation, a 501(c)(3) charitable organization established to raise awareness of and funds to develop cures for all forms of children’s interstitial and diffuse lung diseases.
Mr. Danson graduated with honors from Bernard M. Baruch College with a BBA in Accounting and was a MBA candidate in Taxation. He is a certified public accountant and a member of the American Institute and New York State Societies of Certified Public Accountants.